Nothing Special   »   [go: up one dir, main page]

TW200639176A - Crystal of 1-methyl carbapenem compound - Google Patents

Crystal of 1-methyl carbapenem compound

Info

Publication number
TW200639176A
TW200639176A TW095116812A TW95116812A TW200639176A TW 200639176 A TW200639176 A TW 200639176A TW 095116812 A TW095116812 A TW 095116812A TW 95116812 A TW95116812 A TW 95116812A TW 200639176 A TW200639176 A TW 200639176A
Authority
TW
Taiwan
Prior art keywords
crystal
carbapenem compound
methyl carbapenem
compound
methyl
Prior art date
Application number
TW095116812A
Other languages
Chinese (zh)
Inventor
Makoto Michida
Satoshi Kobayashi
Original Assignee
Sankyo Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sankyo Co filed Critical Sankyo Co
Publication of TW200639176A publication Critical patent/TW200639176A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D477/00—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring
    • C07D477/10—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 4, and with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2
    • C07D477/12—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 4, and with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2 with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached in position 6
    • C07D477/16—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 4, and with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2 with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached in position 6 with hetero atoms or carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 3
    • C07D477/20—Sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention provides a crystal of the compound of the following formula (I), The crystal of the 1-methylcarbapenem compound (I) is characterized by that it appears the specific main peak in the powdery X ray diffraction obtained from irradiating K α ray of copper.
TW095116812A 2005-05-13 2006-05-12 Crystal of 1-methyl carbapenem compound TW200639176A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2005140683 2005-05-13

Publications (1)

Publication Number Publication Date
TW200639176A true TW200639176A (en) 2006-11-16

Family

ID=37396657

Family Applications (1)

Application Number Title Priority Date Filing Date
TW095116812A TW200639176A (en) 2005-05-13 2006-05-12 Crystal of 1-methyl carbapenem compound

Country Status (5)

Country Link
US (1) US20080227768A1 (en)
EP (1) EP1880997A4 (en)
JP (1) JPWO2006121151A1 (en)
TW (1) TW200639176A (en)
WO (1) WO2006121151A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101284831A (en) * 2003-08-25 2008-10-15 三共株式会社 Crystal of 1-methyl carbapenem compound
BRPI0608931A2 (en) * 2005-03-22 2010-11-09 Daiichi Sankyo Co Ltd compound or a salt thereof, and process for the preparation thereof
CH698729B1 (en) * 2007-05-30 2009-10-15 Cerbios Pharma Sa Stable crystalline (6S) -N (5) -methyl-5, 6,7,8-tetrahydrofolic acid.

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ298246B6 (en) * 1995-12-21 2007-08-01 Sankyo Company Limited 1-methylcarbapenem derivatives, process of their preparation and pharmaceutical composition in which the derivatives are comprised
TWI250160B (en) * 1999-07-06 2006-03-01 Sankyo Co Crystalline 1-methylcarbapenem compound
US7041660B2 (en) * 1999-07-06 2006-05-09 Sankyo Company, Limited Crystalline 1-methylcarbapenem derivatives
JP4327424B2 (en) * 2000-05-15 2009-09-09 武田薬品工業株式会社 Crystal production method
ES2293988T3 (en) * 2000-05-15 2008-04-01 Takeda Pharmaceutical Company Limited PROCEDURE TO PRODUCE A CRYSTAL.
JP3681116B2 (en) * 2000-09-14 2005-08-10 三共株式会社 Antibacterial agent containing crystalline carbapenem compound
WO2003010152A1 (en) * 2001-07-27 2003-02-06 Yamanouchi Pharmaceutical Co., Ltd. Novel crystal of arylethenesulfonamide derivative and process for producing the same
JP2003277374A (en) * 2002-03-19 2003-10-02 Nippon Kayaku Co Ltd New method for producing pyrimidone acetamide, and crystal thereof
CN101284831A (en) * 2003-08-25 2008-10-15 三共株式会社 Crystal of 1-methyl carbapenem compound
BRPI0608931A2 (en) * 2005-03-22 2010-11-09 Daiichi Sankyo Co Ltd compound or a salt thereof, and process for the preparation thereof
WO2008026556A1 (en) * 2006-08-29 2008-03-06 Daiichi Sankyo Company, Limited Freeze-dried preparation of 1-methylcarbapenem

Also Published As

Publication number Publication date
JPWO2006121151A1 (en) 2008-12-18
WO2006121151A1 (en) 2006-11-16
EP1880997A1 (en) 2008-01-23
EP1880997A4 (en) 2009-03-11
US20080227768A1 (en) 2008-09-18

Similar Documents

Publication Publication Date Title
WO2007085895A3 (en) Fap inhibitors
RS51954B (en) Crystalline modifications to pyraclostrobin
TW200640924A (en) VEGF-R2 inhibitors and methods
SI1853588T1 (en) Chemical compounds
PL1891004T3 (en) Pentafluorosulphanyl-substituted compound and its use for producing medicaments
TN2012000063A1 (en) Quinazolines as potassium ion channel inhibitors
RS51445B (en) Pyrrolidinedione substituted piperidine-phtalazones as pde4 inhibitors
MXPA05012680A (en) Novel substituted 3-sulfur indoles.
MX2007014172A (en) Processes for production of phenolic 4-biphenylylazetidin-2-ones.
MY150971A (en) Mineral amino acid polysaccharide complex
UA94833C2 (en) Substituted bicyclolactams
TW200510303A (en) Novel compounds
TW200626068A (en) Active compounds for seed treatment
TW200637866A (en) Amino-imidazolones for the inhibition of β-secretase
MX2010002902A (en) Anti-infective pyrimidines and uses thereof.
CY1112467T1 (en) 1-SULF-D-GLYCITOLIS PRODUCT
MY159850A (en) Tetracyclic compounds
WO2007008684A3 (en) Ligands of melanocortin receptors
MY148299A (en) Iron-carbohydrate complex compounds
MX2008016039A (en) Glucan preparations.
UA102817C2 (en) Normal;heading 1;heading 2;heading 3;PROCESS FOR AGOMELATINE SYNTHESIS
MY144782A (en) Glucuronate salt of a piperazine compound
UA102220C2 (en) Normal;heading 1;heading 2;heading 3;PROCESS FOR THE SYNTHESIS OF AGOMELATINE
MX2009005649A (en) Treatment for multiple myeloma.
WO2008053334A3 (en) An improved process for preparing rosuvastatin calcium